Recurrence Score<sup>®</sup> Result Impacts Treatment Decisions in Hormone Receptor-Positive, HER2-Negative Patients with Early Breast Cancer in a Real-World Setting—Results of the IRMA Trial
Background: Patients with hormone receptor-positive (HR+), HER2-negative (HER2−) early breast cancer (eBC) with a high risk of relapse often undergo adjuvant chemotherapy. However, only a few patients will gain benefit from chemotherapy. Since classical tumor characteristics (grade, tumor size, lymp...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-10-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/21/5365 |
| _version_ | 1797468862093983744 |
|---|---|
| author | Dominik Dannehl Tobias Engler Lea L. Volmer Annette Staebler Anna K. Fischer Martin Weiss Markus Hahn Christina B. Walter Eva-Maria Grischke Falko Fend Florin-Andrei Taran Sara Y. Brucker Andreas D. Hartkopf |
| author_facet | Dominik Dannehl Tobias Engler Lea L. Volmer Annette Staebler Anna K. Fischer Martin Weiss Markus Hahn Christina B. Walter Eva-Maria Grischke Falko Fend Florin-Andrei Taran Sara Y. Brucker Andreas D. Hartkopf |
| author_sort | Dominik Dannehl |
| collection | DOAJ |
| description | Background: Patients with hormone receptor-positive (HR+), HER2-negative (HER2−) early breast cancer (eBC) with a high risk of relapse often undergo adjuvant chemotherapy. However, only a few patients will gain benefit from chemotherapy. Since classical tumor characteristics (grade, tumor size, lymph node involvement, and Ki67) are of limited value to predict chemotherapy efficacy, multigene expression assays such as the Oncotype DX<sup>®</sup> test were developed to reduce over- and undertreatment. The IRMA trial analyzed the impact of Recurrence Score<sup>®</sup> (RS) assessment on adjuvant treatment recommendations. Materials and methods: The RS result was assessed in patients with HR+/HER2− unilateral eBC with 0–3 pathologic lymph nodes who underwent primary surgical treatment at the Department for Women’s Health of Tuebingen University, Germany. Therapy recommendations without knowledge of the RS result were compared to therapy recommendations with awareness of the RS result. Results: In total, 245 patients underwent RS assessment. Without knowledge of the RS result, 92/245 patients (37.6%) would have been advised to receive chemotherapy. After RS assessment, 56/245 patients (22.9%) were advised to undergo chemotherapy. Chemotherapy was waived in 47/92 patients (51.1%) that were initially recommended to receive it. Chemotherapy was added in 11/153 patients (7.2%) that were recommended to not receive it initially. Summary: Using the RS result to guide adjuvant treatment decisions in HR+/HER2− breast cancer led to a substantial reduction of chemotherapy. In view of the results achieved in prospective studies, the RS result is among other risk-factors suitable for the individualization of adjuvant systemic therapy. |
| first_indexed | 2024-03-09T19:12:19Z |
| format | Article |
| id | doaj.art-80f0271338674847bbda4b6357a63e51 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-09T19:12:19Z |
| publishDate | 2022-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-80f0271338674847bbda4b6357a63e512023-11-24T04:03:18ZengMDPI AGCancers2072-66942022-10-011421536510.3390/cancers14215365Recurrence Score<sup>®</sup> Result Impacts Treatment Decisions in Hormone Receptor-Positive, HER2-Negative Patients with Early Breast Cancer in a Real-World Setting—Results of the IRMA TrialDominik Dannehl0Tobias Engler1Lea L. Volmer2Annette Staebler3Anna K. Fischer4Martin Weiss5Markus Hahn6Christina B. Walter7Eva-Maria Grischke8Falko Fend9Florin-Andrei Taran10Sara Y. Brucker11Andreas D. Hartkopf12Department for Womens’ Health, Tuebingen University, 72076 Tübingen, GermanyDepartment for Womens’ Health, Tuebingen University, 72076 Tübingen, GermanyDepartment for Womens’ Health, Tuebingen University, 72076 Tübingen, GermanyDepartment for Pathology and Neuropathology, Tuebingen University, 72076 Tübingen, GermanyDepartment for Pathology and Neuropathology, Tuebingen University, 72076 Tübingen, GermanyDepartment for Womens’ Health, Tuebingen University, 72076 Tübingen, GermanyDepartment for Womens’ Health, Tuebingen University, 72076 Tübingen, GermanyDepartment for Womens’ Health, Tuebingen University, 72076 Tübingen, GermanyDepartment for Womens’ Health, Tuebingen University, 72076 Tübingen, GermanyDepartment for Pathology and Neuropathology, Tuebingen University, 72076 Tübingen, GermanyDepartment for Gynecology and Obstetrics, Freiburg University, 79085 Freiburg im Breisgau, GermanyDepartment for Womens’ Health, Tuebingen University, 72076 Tübingen, GermanyDepartment for Womens’ Health, Tuebingen University, 72076 Tübingen, GermanyBackground: Patients with hormone receptor-positive (HR+), HER2-negative (HER2−) early breast cancer (eBC) with a high risk of relapse often undergo adjuvant chemotherapy. However, only a few patients will gain benefit from chemotherapy. Since classical tumor characteristics (grade, tumor size, lymph node involvement, and Ki67) are of limited value to predict chemotherapy efficacy, multigene expression assays such as the Oncotype DX<sup>®</sup> test were developed to reduce over- and undertreatment. The IRMA trial analyzed the impact of Recurrence Score<sup>®</sup> (RS) assessment on adjuvant treatment recommendations. Materials and methods: The RS result was assessed in patients with HR+/HER2− unilateral eBC with 0–3 pathologic lymph nodes who underwent primary surgical treatment at the Department for Women’s Health of Tuebingen University, Germany. Therapy recommendations without knowledge of the RS result were compared to therapy recommendations with awareness of the RS result. Results: In total, 245 patients underwent RS assessment. Without knowledge of the RS result, 92/245 patients (37.6%) would have been advised to receive chemotherapy. After RS assessment, 56/245 patients (22.9%) were advised to undergo chemotherapy. Chemotherapy was waived in 47/92 patients (51.1%) that were initially recommended to receive it. Chemotherapy was added in 11/153 patients (7.2%) that were recommended to not receive it initially. Summary: Using the RS result to guide adjuvant treatment decisions in HR+/HER2− breast cancer led to a substantial reduction of chemotherapy. In view of the results achieved in prospective studies, the RS result is among other risk-factors suitable for the individualization of adjuvant systemic therapy.https://www.mdpi.com/2072-6694/14/21/5365oncotype DXrecurrence scorebreast cancerindividualized therapy |
| spellingShingle | Dominik Dannehl Tobias Engler Lea L. Volmer Annette Staebler Anna K. Fischer Martin Weiss Markus Hahn Christina B. Walter Eva-Maria Grischke Falko Fend Florin-Andrei Taran Sara Y. Brucker Andreas D. Hartkopf Recurrence Score<sup>®</sup> Result Impacts Treatment Decisions in Hormone Receptor-Positive, HER2-Negative Patients with Early Breast Cancer in a Real-World Setting—Results of the IRMA Trial Cancers oncotype DX recurrence score breast cancer individualized therapy |
| title | Recurrence Score<sup>®</sup> Result Impacts Treatment Decisions in Hormone Receptor-Positive, HER2-Negative Patients with Early Breast Cancer in a Real-World Setting—Results of the IRMA Trial |
| title_full | Recurrence Score<sup>®</sup> Result Impacts Treatment Decisions in Hormone Receptor-Positive, HER2-Negative Patients with Early Breast Cancer in a Real-World Setting—Results of the IRMA Trial |
| title_fullStr | Recurrence Score<sup>®</sup> Result Impacts Treatment Decisions in Hormone Receptor-Positive, HER2-Negative Patients with Early Breast Cancer in a Real-World Setting—Results of the IRMA Trial |
| title_full_unstemmed | Recurrence Score<sup>®</sup> Result Impacts Treatment Decisions in Hormone Receptor-Positive, HER2-Negative Patients with Early Breast Cancer in a Real-World Setting—Results of the IRMA Trial |
| title_short | Recurrence Score<sup>®</sup> Result Impacts Treatment Decisions in Hormone Receptor-Positive, HER2-Negative Patients with Early Breast Cancer in a Real-World Setting—Results of the IRMA Trial |
| title_sort | recurrence score sup r sup result impacts treatment decisions in hormone receptor positive her2 negative patients with early breast cancer in a real world setting results of the irma trial |
| topic | oncotype DX recurrence score breast cancer individualized therapy |
| url | https://www.mdpi.com/2072-6694/14/21/5365 |
| work_keys_str_mv | AT dominikdannehl recurrencescoresupsupresultimpactstreatmentdecisionsinhormonereceptorpositiveher2negativepatientswithearlybreastcancerinarealworldsettingresultsoftheirmatrial AT tobiasengler recurrencescoresupsupresultimpactstreatmentdecisionsinhormonereceptorpositiveher2negativepatientswithearlybreastcancerinarealworldsettingresultsoftheirmatrial AT lealvolmer recurrencescoresupsupresultimpactstreatmentdecisionsinhormonereceptorpositiveher2negativepatientswithearlybreastcancerinarealworldsettingresultsoftheirmatrial AT annettestaebler recurrencescoresupsupresultimpactstreatmentdecisionsinhormonereceptorpositiveher2negativepatientswithearlybreastcancerinarealworldsettingresultsoftheirmatrial AT annakfischer recurrencescoresupsupresultimpactstreatmentdecisionsinhormonereceptorpositiveher2negativepatientswithearlybreastcancerinarealworldsettingresultsoftheirmatrial AT martinweiss recurrencescoresupsupresultimpactstreatmentdecisionsinhormonereceptorpositiveher2negativepatientswithearlybreastcancerinarealworldsettingresultsoftheirmatrial AT markushahn recurrencescoresupsupresultimpactstreatmentdecisionsinhormonereceptorpositiveher2negativepatientswithearlybreastcancerinarealworldsettingresultsoftheirmatrial AT christinabwalter recurrencescoresupsupresultimpactstreatmentdecisionsinhormonereceptorpositiveher2negativepatientswithearlybreastcancerinarealworldsettingresultsoftheirmatrial AT evamariagrischke recurrencescoresupsupresultimpactstreatmentdecisionsinhormonereceptorpositiveher2negativepatientswithearlybreastcancerinarealworldsettingresultsoftheirmatrial AT falkofend recurrencescoresupsupresultimpactstreatmentdecisionsinhormonereceptorpositiveher2negativepatientswithearlybreastcancerinarealworldsettingresultsoftheirmatrial AT florinandreitaran recurrencescoresupsupresultimpactstreatmentdecisionsinhormonereceptorpositiveher2negativepatientswithearlybreastcancerinarealworldsettingresultsoftheirmatrial AT saraybrucker recurrencescoresupsupresultimpactstreatmentdecisionsinhormonereceptorpositiveher2negativepatientswithearlybreastcancerinarealworldsettingresultsoftheirmatrial AT andreasdhartkopf recurrencescoresupsupresultimpactstreatmentdecisionsinhormonereceptorpositiveher2negativepatientswithearlybreastcancerinarealworldsettingresultsoftheirmatrial |